1101 Hamlin Rd
3 articles with KBI Biopharma
ZyVersa Therapeutics to Advance Development of Its Lead Inflammasome Inhibitor with Selexis and KBI Biopharma’s Integrated Development Platform
JSR Life Sciences Companies Selexis SA and KBI Biopharma, Inc. have announced a new collaboration with ZyVersa Therapeutics to advance development of ZyVersa’s lead inflammasome inhibitor, IC 100, for the treatment of multiple inflammatory conditions.
JSR affiliate companies Crown Bioscience, KBI Biopharma, Inc., Medical & Biological Laboratories Co., LTD., Selexis SA and other affiliates throughout Europe and the Asia-Pacific region.
KBI Biopharma, Inc. and Selexis SA announced today they have appointed four leading, internationally recognized scientists to their newly formed Joint Scientific Advisory Board (JSAB).